FindTrial
Sign In

use of white blood cell counts in early diagnosis of colorectal carcinomas

Implication of derived leucocytes ratio as a screening marker in colorectal carcinomas

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/01/048944
Enrollment
147
Registered
2023-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K928- Other specified diseases of the digestive system

Interventions

None listed

Sponsors

Kasturba medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All people undergoing colonoscopy for colorectal pathologies and who have undergone complete blood count will be included.

Exclusion criteria

Exclusion criteria: People with no complete blood counts test done will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
To check for any rise in the neutrophils and fall in the lymphocytes leading to an elevated Derived leucocyte ratio(DLR) in patients with colorectal cancer.Timepoint: complete bloood count at the time of colonoscopy—

Secondary

MeasureTime frame
To check if the elevated Derived lymphocyte ratio (DLR) can be used as a screening marker for colorectal carcinomas.Timepoint: complete bloood count at the time of colonoscopy—

Countries

India

Contacts

Public ContactDr Veena L Karanth

Kasturba Medical College, Manipal

veena.karanth@manipal.edu9845417715

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026